Teva Pharmaceutical Industries LimitedTeva Pharmaceutical Industries LimitedTeva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪19.72 B‬USD
−1.14USD
‪−1.64 B‬USD
‪16.51 B‬USD
‪1.15 B‬
Beta (1Y)
0.41

About TEVA


CEO
Richard Francis
Headquarters
Tel Aviv
Founded
1901
FIGI
BBG000C0CD58
Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: United States, Europe, and International Markets. The United States segment focuses on therapeutic area of central nervous system (CNS) portfolio, and is involved in the distribution business of generic, biosimilar and medicines, and over-the-counter (OTC) pharmaceutical products from the firm and third-party manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals, and physician offices in the United States. The Europe segment offers OTC portfolio including SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brands in European Union, the United Kingdom, and certain other European countries. The International Markets segment provides its products to countries such as Canada, Israel, Russia, Latin America, and Japan. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Check out other big names from the same industry as TEVA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
TEVA.GJ
Teva Pharmaceutical Finance Co. LLC 0.25% 01-FEB-2026
Yield to maturity
26.91%
Maturity date
Feb 1, 2026
US88167AAF84
TEVA PHARMA FIN III 4.10% CALL 01OT46
Yield to maturity
7.44%
Maturity date
Oct 1, 2046
US88163VAD10
TEVA PHARM FIN CO LLC 6.15% CALL 01FB36
Yield to maturity
5.75%
Maturity date
Feb 1, 2036
CH0333827506
TEVA 1% 25
Yield to maturity
5.62%
Maturity date
Jul 28, 2025
TFAB
TEVA P.FI.NL III 16/26
Yield to maturity
5.22%
Maturity date
Oct 1, 2026
TFAF
TEVA P.FI.NL III 18/28
Yield to maturity
5.13%
Maturity date
Mar 1, 2028

See all TEVA bonds